Don't forget DS. If BTA gets the funding to finish Lani licensing of ROW, DS can easily expend its manufacturing capacity to supply the ROW market, and of course will make a lot of money out of that.
Just don't know what plan BTA management has got for Lani. PC's "normalized relationship" with GSK is a big worry.
Just my thoughts.
Add to My Watchlist
What is My Watchlist?